Simon Fifer
Simon Fifer has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Puig
Johnson and Johnson Australia
3 shared publications - Brittany Keen
Community and Patient Preference Research, Sydney, NSW, Australia
3 shared publications - Ariana Cabrera
Community and Patient Preference Research Pty Ltd, CaPPRe, Level 5, 478 George St, Sydney, Australia
2 shared publications Bronwyn West
2 shared publicationsKatherine Young
CSL Seqirus
2 shared publicationsLili Toh
Community and Patient Preference Research (CaPPRe) Pty Ltd, Sydney, New South Wales, Australia
2 shared publications
Latest Publications
- Open Access
- 20 June 2026
- Published by Springer Nature in Health and Quality of Life Outcomes
Patient and carer treatment preferences for oral medication in chronic kidney disease: a discrete choice experiment across eight countries
Background: Chronic Kidney Disease (CKD) affects over 674 million people globally and can lead to kidney failure, which significantly impairs quality and duration of life. While various oral pharmacological treatment options are available, limited research exists on how patients and carers prioritise treatment attributes. This study explored preferences for oral CKD medication across eight countries, involving 2,324 participants (1,511 patients and 813 carers). Methods: A Discrete Choice Experiment (DCE) was conducted in which participants completed seven hypothetical scenarios, each with two unlabelled treatment options and a “neither” (or “stay on current treatment”) option. Five attributes were assessed: delay in dialysis or transplant, life extension, reduced risk of heart failure hospitalisation, risk of side effects, and out-of-pocket costs. Data were analysed using Mixed Multinomial Logit models, generating separate patient and carer models for each country (16 models), enabling cross-country comparisons. Results: Participants across countries placed the highest importance on delaying dialysis or transplant, followed by life extension, with minimising treatment side effects ranked next. They preferred longer delays for dialysis or transplant, with the seven-year delay being most preferred. Regional and patient-carer variations were observed in attribute importance. Model parameters were used to calculate utility for treatment profiles and simulate preference shares, enabling country-level comparisons. Conclusion: Patients and carers consistently prioritised oral medications that delay the need for dialysis or transplant and extend life, although the relative importance of these attributes differed by country and respondent group. The choice of oral medication in CKD is preference-sensitive, and these results have direct implications for shared decision-making in clinical practice. To support application of these findings, we have developed an interactive dashboard that simulates the impact of medication attributes on predicted uptake across all eight countries: https://cappre.shinyapps.io/CKD_Dapa_DCE/ .
- 20 June 2026
- Published by Springer Nature in Health and Quality of Life Outcomes
Open AccessPatient and carer treatment preferences for oral medication in chronic kidney disease: a discrete choice experiment across eight countries
Background: Chronic Kidney Disease (CKD) affects over 674 million people globally and can lead to kidney failure, which significantly impairs quality and duration of life. While various oral pharmacological treatment options are available, limited research exists on how patients and carers prioritise treatment attributes. This study explored preferences for oral CKD medication across eight countries, involving 2,324 participants (1,511 patients and 813 carers). Methods: A Discrete Choice Experiment (DCE) was conducted in which participants completed seven hypothetical scenarios, each with two unlabelled treatment options and a “neither” (or “stay on current treatment”) option. Five attributes were assessed: delay in dialysis or transplant, life extension, reduced risk of heart failure hospitalisation, risk of side effects, and out-of-pocket costs. Data were analysed using Mixed Multinomial Logit models, generating separate patient and carer models for each country (16 models), enabling cross-country comparisons. Results: Participants across countries placed the highest importance on delaying dialysis or transplant, followed by life extension, with minimising treatment side effects ranked next. They preferred longer delays for dialysis or transplant, with the seven-year delay being most preferred. Regional and patient-carer variations were observed in attribute importance. Model parameters were used to calculate utility for treatment profiles and simulate preference shares, enabling country-level comparisons. Conclusion: Patients and carers consistently prioritised oral medications that delay the need for dialysis or transplant and extend life, although the relative importance of these attributes differed by country and respondent group. The choice of oral medication in CKD is preference-sensitive, and these results have direct implications for shared decision-making in clinical practice. To support application of these findings, we have developed an interactive dashboard that simulates the impact of medication attributes on predicted uptake across all eight countries: https://cappre.shinyapps.io/CKD_Dapa_DCE/ .
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 20, 1-14
Experiences, Values and Goals of People Living with Obstructive Hypertrophic Cardiomyopathy: Exploratory Patient Interviews
Purpose: This qualitative study explored the experiences, values and goals of patients living with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Patients and Methods: A cohort of patients were recruited between March and August 2023 via the Australian Genetic Heart Disease Registry and Cardiomyopathy Association of Australia. Patients were eligible if aged 18 years or older, English speaking and diagnosed with obstructive HCM, with symptomatic status reflective of New York Heart Association class II and above. Patients first completed the Kansas City Cardiomyopathy Questionnaire (KCCQ-23) and then underwent a 60– 75-minute semi-structured video interview. Interviews were analyzed using thematic analysis, which was facilitated by NVivo software. Results: Ten patients participated in structured interviews (6 women and 4 men, mean age: 64.5 years). All were receiving pharmacologic therapy and 50% had undergone septal reduction therapy. Results showed that patients continue to experience notable impact from their obstructive HCM (KCCQ-23 summary score: 63.6; clinical summary score: 66.1). Patients frequently reported living with symptoms for years before diagnosis, often attributing limitations to poor fitness. Symptom burden was substantial, including dyspnea, fatigue, palpitations, chest pain, dizziness and syncope, with variability linked to exertion and environmental factors. Emotional responses ranged from resilience to anxiety, frustration, and fear of sudden death. Lifestyle adjustments were common: patients limited physical activity, modified daily routines, and reduced social engagement. Treatment goals prioritized efficacy and safety, with strong preference for therapies that alleviate symptoms and improve quality of life. Patients valued delaying surgery and favoured oral, once-daily regimens, while placing little importance on objective clinical measures (e.g. echocardiographic findings). Conclusion: The study provides a unique window into lived experiences of patients with symptomatic obstructive HCM in Australia, demonstrating the impact extends far beyond symptoms. It highlights the need to consider individual patient priorities and treatment goals to provide a tailored, patient‑centric approach.
- 1 May 2026
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 20, 1-14
Open AccessExperiences, Values and Goals of People Living with Obstructive Hypertrophic Cardiomyopathy: Exploratory Patient Interviews
Purpose: This qualitative study explored the experiences, values and goals of patients living with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Patients and Methods: A cohort of patients were recruited between March and August 2023 via the Australian Genetic Heart Disease Registry and Cardiomyopathy Association of Australia. Patients were eligible if aged 18 years or older, English speaking and diagnosed with obstructive HCM, with symptomatic status reflective of New York Heart Association class II and above. Patients first completed the Kansas City Cardiomyopathy Questionnaire (KCCQ-23) and then underwent a 60– 75-minute semi-structured video interview. Interviews were analyzed using thematic analysis, which was facilitated by NVivo software. Results: Ten patients participated in structured interviews (6 women and 4 men, mean age: 64.5 years). All were receiving pharmacologic therapy and 50% had undergone septal reduction therapy. Results showed that patients continue to experience notable impact from their obstructive HCM (KCCQ-23 summary score: 63.6; clinical summary score: 66.1). Patients frequently reported living with symptoms for years before diagnosis, often attributing limitations to poor fitness. Symptom burden was substantial, including dyspnea, fatigue, palpitations, chest pain, dizziness and syncope, with variability linked to exertion and environmental factors. Emotional responses ranged from resilience to anxiety, frustration, and fear of sudden death. Lifestyle adjustments were common: patients limited physical activity, modified daily routines, and reduced social engagement. Treatment goals prioritized efficacy and safety, with strong preference for therapies that alleviate symptoms and improve quality of life. Patients valued delaying surgery and favoured oral, once-daily regimens, while placing little importance on objective clinical measures (e.g. echocardiographic findings). Conclusion: The study provides a unique window into lived experiences of patients with symptomatic obstructive HCM in Australia, demonstrating the impact extends far beyond symptoms. It highlights the need to consider individual patient priorities and treatment goals to provide a tailored, patient‑centric approach.
- Open Access
- 12 November 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (21) , e71323
Attribute Preferences for Somatostatin Analogues in Neuroendocrine Tumours ( NETs ) Among Patients, Clinicians and Nurses in Australia
Background: Long‐acting somatostatin analogues (LA SSAs) are commonly used as first‐line treatment in well‐differentiated low and intermediate grade 1–2 gastroenteropancreatic neuroendocrine tumours (GEP‐NETs). As a long‐term treatment option for NETs, treatment preferences should be taken into consideration. The objective of this study is to evaluate the relative importance of different LA SSA treatment features among patients with NETs, clinicians and nurses in Australia. Methods: A discrete choice experiment (DCE) method was used to analyse treatment preferences for NETs, embedded in an online survey. Participants could choose between three hypothetical treatment options: ‘deep subcutaneous injectable treatment’, ‘deep intramuscular injectable treatment’, ‘oral treatment’; and an opt‐out. Each option was described by seven attributes: ‘Progression free survival’ (PFS), ‘symptom control for diarrhoea and flushing’, ‘risk of gastrointestinal (GI) side effects’, ‘frequency of administration’, ‘treatment administration,’ ‘treatment delivery,’ and ‘availability of patient support’. A Mixed Multinomial Logit model (MMNL) was used for analysis. Results: A total of 54 patients with NETs, 27 clinicians, and 9 nurses completed the DCE (of 33, 26 and 20 planned respectively). The statistical model showed an overall preference for oral administration. ‘PFS’ was the most important attribute, followed by ‘symptom control for diarrhoea and flushing’ and ‘risk of GI side effects’. ‘PFS’ and ‘symptom control for diarrhoea and flushing’ were also found to be more important to healthcare professionals (HCPs, i.e., clinicians and nurses) than patients with NETs, while the attributes ‘symptom control for diarrhoea and flushing’ and ‘risk of GI side effects’ were found to be more important in non‐metropolitan areas (vs. metropolitan areas). Conclusions: Analysis showed how patients with NETs and HCPs prioritise treatment attributes for NETs differently. Because the duration of use of LA SSA for the treatment of NETs is often long, these differences highlight the importance of involving the patient when making treatment decisions.
- 12 November 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (21) , e71323
Open AccessAttribute Preferences for Somatostatin Analogues in Neuroendocrine Tumours ( NETs ) Among Patients, Clinicians and Nurses in Australia
Background: Long‐acting somatostatin analogues (LA SSAs) are commonly used as first‐line treatment in well‐differentiated low and intermediate grade 1–2 gastroenteropancreatic neuroendocrine tumours (GEP‐NETs). As a long‐term treatment option for NETs, treatment preferences should be taken into consideration. The objective of this study is to evaluate the relative importance of different LA SSA treatment features among patients with NETs, clinicians and nurses in Australia. Methods: A discrete choice experiment (DCE) method was used to analyse treatment preferences for NETs, embedded in an online survey. Participants could choose between three hypothetical treatment options: ‘deep subcutaneous injectable treatment’, ‘deep intramuscular injectable treatment’, ‘oral treatment’; and an opt‐out. Each option was described by seven attributes: ‘Progression free survival’ (PFS), ‘symptom control for diarrhoea and flushing’, ‘risk of gastrointestinal (GI) side effects’, ‘frequency of administration’, ‘treatment administration,’ ‘treatment delivery,’ and ‘availability of patient support’. A Mixed Multinomial Logit model (MMNL) was used for analysis. Results: A total of 54 patients with NETs, 27 clinicians, and 9 nurses completed the DCE (of 33, 26 and 20 planned respectively). The statistical model showed an overall preference for oral administration. ‘PFS’ was the most important attribute, followed by ‘symptom control for diarrhoea and flushing’ and ‘risk of GI side effects’. ‘PFS’ and ‘symptom control for diarrhoea and flushing’ were also found to be more important to healthcare professionals (HCPs, i.e., clinicians and nurses) than patients with NETs, while the attributes ‘symptom control for diarrhoea and flushing’ and ‘risk of GI side effects’ were found to be more important in non‐metropolitan areas (vs. metropolitan areas). Conclusions: Analysis showed how patients with NETs and HCPs prioritise treatment attributes for NETs differently. Because the duration of use of LA SSA for the treatment of NETs is often long, these differences highlight the importance of involving the patient when making treatment decisions.
- Open Access
- 21 December 2024
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2440164
Australian preferences for influenza vaccine attributes and cost: A discrete choice experiment
People in Australia have access to different influenza vaccines, but may be unaware of their options and features. Preference studies for differentiated influenza vaccines including cell-based vaccines are limited, particularly in Australia. This study investigated which influenza vaccine attributes people in Australia value using a discrete choice experiment (DCE). Adults in Australia ineligible for free influenza vaccines had been vaccinated in the last 5 years and intended to be vaccinated again completed an online survey. Participants (N = 1203) were presented three influenza vaccine profiles described by eight attributes. Half the DCE scenarios described influenza season severity to be the same as last year, and the other half as more severe. DCE data were analyzed using a mixed multinomial logit (MMNL) model. All eight attributes significantly predicted vaccine choice (p < .05). Regardless of influenza season severity, participants preferred a vaccine: with greater protection, designed to be an exact match to circulating strains (match), using modern technology, manufactured by an Australian company, available at pharmacies, preferred by health care professionals (HCP), government funded for high-risk individuals and having lower cost. The top three attributes by importance were protection, match and cost. Participants were willing to pay more for match and higher protection. The Marginal Willingness to Pay (MWTP) for the most important attributes, excluding cost, were AUD $1.61/$2.18 for each additional percent in protection (same/more severe season), AUD $25.37/$32.37 for match and AUD $4.06/$15.97 for HCP preference. Findings indicate that match, protection, cost and HCP preference are key to vaccine choice, highlighting the importance of shared decision-making.
- 21 December 2024
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2440164
Open AccessAustralian preferences for influenza vaccine attributes and cost: A discrete choice experiment
People in Australia have access to different influenza vaccines, but may be unaware of their options and features. Preference studies for differentiated influenza vaccines including cell-based vaccines are limited, particularly in Australia. This study investigated which influenza vaccine attributes people in Australia value using a discrete choice experiment (DCE). Adults in Australia ineligible for free influenza vaccines had been vaccinated in the last 5 years and intended to be vaccinated again completed an online survey. Participants (N = 1203) were presented three influenza vaccine profiles described by eight attributes. Half the DCE scenarios described influenza season severity to be the same as last year, and the other half as more severe. DCE data were analyzed using a mixed multinomial logit (MMNL) model. All eight attributes significantly predicted vaccine choice (p < .05). Regardless of influenza season severity, participants preferred a vaccine: with greater protection, designed to be an exact match to circulating strains (match), using modern technology, manufactured by an Australian company, available at pharmacies, preferred by health care professionals (HCP), government funded for high-risk individuals and having lower cost. The top three attributes by importance were protection, match and cost. Participants were willing to pay more for match and higher protection. The Marginal Willingness to Pay (MWTP) for the most important attributes, excluding cost, were AUD $1.61/$2.18 for each additional percent in protection (same/more severe season), AUD $25.37/$32.37 for match and AUD $4.06/$15.97 for HCP preference. Findings indicate that match, protection, cost and HCP preference are key to vaccine choice, highlighting the importance of shared decision-making.
- Open Access
- 1 December 2024
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 40 (S1) , S35
OP80 Generating Patient Preference Evidence For Health Technology Assessment: A Sustainable Roadmap
Introduction: Research with members of health technology assessment (HTA) bodies has uncovered key barriers to integrating patient preference (PP) data into HTA, including concerns about resources/time constraints and a lack of clarity around who is responsible for data generation. We sought to develop a roadmap that addresses these issues, outlining the roles and responsibilities of different stakeholders to foster more sustainable PP data generation.Methods: Based on a forthcoming article to be published in The Patient, this roadmap consists of a step-by-step approach for PP evidence generation. Real-world case studies and literature will be used to illustrate each stage, from identifying priority treatment areas and evidence gaps, forming a steering committee and engaging HTA members, to securing syndicated funding and disseminating results with full transparency.Results: In contrast to standard approaches to data generation, this roadmap focuses on proactive data collection, collaborating with those who will ultimately use the data (HTA), and pooling resources to mitigate costs and the risk of bias. The roadmap can be applied to all preference-sensitive treatment areas and across health systems/countries. It is designed to be a continuous process, whereby preferences are regularly updated to align with changes to the treatment landscape. A graphic summary of the roadmap is available for viewing at this link: https://cappre.info/images/HTAprocess.pdfConclusions: Patient preference data has the potential to make healthcare decision-making more informed, socially legitimate, transparent, and accountable to the patient community. However, current approaches to capturing PP data can be resource intensive with narrow applicability in their findings. The present roadmap offers an alternative, sustainable solution.
- 1 December 2024
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 40 (S1) , S35
Open AccessOP80 Generating Patient Preference Evidence For Health Technology Assessment: A Sustainable Roadmap
Introduction: Research with members of health technology assessment (HTA) bodies has uncovered key barriers to integrating patient preference (PP) data into HTA, including concerns about resources/time constraints and a lack of clarity around who is responsible for data generation. We sought to develop a roadmap that addresses these issues, outlining the roles and responsibilities of different stakeholders to foster more sustainable PP data generation.Methods: Based on a forthcoming article to be published in The Patient, this roadmap consists of a step-by-step approach for PP evidence generation. Real-world case studies and literature will be used to illustrate each stage, from identifying priority treatment areas and evidence gaps, forming a steering committee and engaging HTA members, to securing syndicated funding and disseminating results with full transparency.Results: In contrast to standard approaches to data generation, this roadmap focuses on proactive data collection, collaborating with those who will ultimately use the data (HTA), and pooling resources to mitigate costs and the risk of bias. The roadmap can be applied to all preference-sensitive treatment areas and across health systems/countries. It is designed to be a continuous process, whereby preferences are regularly updated to align with changes to the treatment landscape. A graphic summary of the roadmap is available for viewing at this link: https://cappre.info/images/HTAprocess.pdfConclusions: Patient preference data has the potential to make healthcare decision-making more informed, socially legitimate, transparent, and accountable to the patient community. However, current approaches to capturing PP data can be resource intensive with narrow applicability in their findings. The present roadmap offers an alternative, sustainable solution.
- Open Access
- 1 December 2024
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 40 (S1) , S35
OP81 Experience Matters: A Discrete Choice Experiment Exploring Patient Preferences For Heart Valve Procedures
Introduction: Treatment for heart valve diseases (HVD) typically involves surgery, but less invasive procedures are becoming more common. Although the two procedures have similar outcomes, the risk–benefit profiles differ, indicating patients should be included in treatment decisions so they align with their values/preferences. This study aimed to determine patients’ preferences for HVD procedures, and the relative importance of treatment attributes.Methods: An online survey with discrete choice experiment (DCE) was disseminated to patients with aortic stenosis, mitral valve regurgitation, and tricuspid valve regurgitation. Participants were presented with several choice sets, each comprising two hypothetical treatment procedures (labeled “invasive procedure” and “minimally invasive procedure”) as well as an opt-out. DCE attributes were selected based on a literature review, qualitative interviews with patients and specialist doctors, and steering committee consultation (patients, patient organization representatives, and cardiac physicians). Responses were collected via healthcare recruiters, online panels, and patient organizations. DCE data from 143 Australian patients was analyzed using a mixed multinomial logit (MMNL) model.Results: Results indicate an “experience effect” whereby patients preferred the same type of treatment they had undergone previously. For example, patients who had undergone a transcatheter procedure were more likely to choose the minimally invasive procedure in the experiment and vice versa for those who had undergone invasive procedures like open-heart surgery. Patients were willing to switch procedures based on its risk–benefit profile, and most patients preferred the minimally invasive procedure when it reflected the profile of transcatheter aortic valve replacement (TAVI), even if they had previous invasive procedures experience. Key attributes driving choice were valve durability and regaining independence.Conclusions: There is a great deal of heterogeneity in HVD patient preferences, even when treatment outcomes appear similar. Patients preferred a minimally invasive procedure over an invasive procedure, irrespective of prior treatment experience with valve durability and independence driving choice. These results can inform healthcare decision-makers about what features of HVD procedures patients value most, taking into consideration patients’ prior experiences.
- 1 December 2024
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 40 (S1) , S35
Open AccessOP81 Experience Matters: A Discrete Choice Experiment Exploring Patient Preferences For Heart Valve Procedures
Introduction: Treatment for heart valve diseases (HVD) typically involves surgery, but less invasive procedures are becoming more common. Although the two procedures have similar outcomes, the risk–benefit profiles differ, indicating patients should be included in treatment decisions so they align with their values/preferences. This study aimed to determine patients’ preferences for HVD procedures, and the relative importance of treatment attributes.Methods: An online survey with discrete choice experiment (DCE) was disseminated to patients with aortic stenosis, mitral valve regurgitation, and tricuspid valve regurgitation. Participants were presented with several choice sets, each comprising two hypothetical treatment procedures (labeled “invasive procedure” and “minimally invasive procedure”) as well as an opt-out. DCE attributes were selected based on a literature review, qualitative interviews with patients and specialist doctors, and steering committee consultation (patients, patient organization representatives, and cardiac physicians). Responses were collected via healthcare recruiters, online panels, and patient organizations. DCE data from 143 Australian patients was analyzed using a mixed multinomial logit (MMNL) model.Results: Results indicate an “experience effect” whereby patients preferred the same type of treatment they had undergone previously. For example, patients who had undergone a transcatheter procedure were more likely to choose the minimally invasive procedure in the experiment and vice versa for those who had undergone invasive procedures like open-heart surgery. Patients were willing to switch procedures based on its risk–benefit profile, and most patients preferred the minimally invasive procedure when it reflected the profile of transcatheter aortic valve replacement (TAVI), even if they had previous invasive procedures experience. Key attributes driving choice were valve durability and regaining independence.Conclusions: There is a great deal of heterogeneity in HVD patient preferences, even when treatment outcomes appear similar. Patients preferred a minimally invasive procedure over an invasive procedure, irrespective of prior treatment experience with valve durability and independence driving choice. These results can inform healthcare decision-makers about what features of HVD procedures patients value most, taking into consideration patients’ prior experiences.
- Open Access
- 30 July 2024
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 35 (1) , 2339440
Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia
Oral systemic and injectable biologic treatments are available in Australia to treat moderate to severe psoriasis. To examine how patients and dermatologists in Australia choose between oral and injectable treatments for psoriasis. In this discrete choice experiment (DCE), adults with moderate to severe psoriasis and dermatologists were asked to choose between 2 treatments labeled by mode of administration ('oral' or 'subcutaneous injection'), each with randomly assigned levels for 9 treatment attributes. Needle fear was rated by patients. Completed surveys from 178 patients and 43 dermatologists were included in the analysis. Symptom reduction, safety, and mode of administration were attributes found to have a significant impact on treatment choice; dosing frequency was a significant attribute for the injectable option. When treatment attributes were held equal, patients and dermatologists preferred oral versus injectable treatments for moderate disease. Patients with higher levels of needle fear were more likely to favor an oral treatment versus patients with lower levels of needle fear. Participation bias may limit the generalizability of these findings. Participants preferred oral over injectable treatment for moderate psoriasis. These findings corroborate the need for efficacious oral therapies to treat the disease.
- 30 July 2024
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 35 (1) , 2339440
Open AccessTradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia
Oral systemic and injectable biologic treatments are available in Australia to treat moderate to severe psoriasis. To examine how patients and dermatologists in Australia choose between oral and injectable treatments for psoriasis. In this discrete choice experiment (DCE), adults with moderate to severe psoriasis and dermatologists were asked to choose between 2 treatments labeled by mode of administration ('oral' or 'subcutaneous injection'), each with randomly assigned levels for 9 treatment attributes. Needle fear was rated by patients. Completed surveys from 178 patients and 43 dermatologists were included in the analysis. Symptom reduction, safety, and mode of administration were attributes found to have a significant impact on treatment choice; dosing frequency was a significant attribute for the injectable option. When treatment attributes were held equal, patients and dermatologists preferred oral versus injectable treatments for moderate disease. Patients with higher levels of needle fear were more likely to favor an oral treatment versus patients with lower levels of needle fear. Participation bias may limit the generalizability of these findings. Participants preferred oral over injectable treatment for moderate psoriasis. These findings corroborate the need for efficacious oral therapies to treat the disease.
- Open Access
- 5 April 2024
- Published by Elsevier in Social Science Research
- Vol. 120, 103013
A new subjective well-being index using anchored best-worst scaling
- 5 April 2024
- Published by Elsevier in Social Science Research
- Vol. 120, 103013
Open AccessA new subjective well-being index using anchored best-worst scaling
- Open Access
- 1 February 2024
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 18, 435-454
Patient and Healthcare Professional Preferences for Prescription Weight Loss Medications in Australia: Two Discrete Choice Experiments
Purpose: Overweight and obesity are common in Australia and among the leading risk factors for ill health. Maintained weight loss of > 5– 10% can prevent and reduce the risk of obesity-related comorbidities. Prescription weight loss medications plus lifestyle interventions can result in additional weight loss compared with lifestyle interventions alone, but these medications are under-prescribed in Australia. Our aim was to develop a greater understanding of the treatment preferences of people with overweight or obesity and the healthcare practitioners (HCPs) who treat them. Participants and Methods: An online survey of Australian adults with overweight or obesity and treating HCPs was conducted in 2020. A discrete choice experiment (DCE) approach was used to determine what is most important to people when evaluating oral and injectable prescription weight loss medications. Participants were asked to choose between three hypothetical treatment alternatives: “Oral pill”; “Subcutaneous injection pen (replaceable needle)”; “Disposable subcutaneous injection pen (hidden needle)”; and an opt-out option (“None of these”). Results: The online survey and DCE were completed by 193 patients and 104 HCPs. For both patients and HCPs, all treatment alternatives (oral, replaceable injection and disposable injection) were preferred over the opt-out. Gastrointestinal side effects, followed by success rate, percentage body weight lost, and cost were the most important attributes to patients. For HCPs, percentage body weight loss was the most important treatment attribute, followed by success rate, gastrointestinal side effects and cost. While most patients reported relatively low needle fear, physicians reported relatively high perceived patient needle fear. Conclusion: Clinician-patient discussions about treatments for weight loss should cover the option of prescription weight loss medications, including injectable medications, which patients may be less apprehensive about than physicians believe. Treatments with a high success rate and low or manageable risk of gastrointestinal side effects may be preferred over alternatives. Plain Language Summary: Overweight and obesity are the leading cause of health problems in Australia. Medications can be effective for people with this condition when combined with diet and exercise changes, but weight-loss medications in Australia are under-used. To understand why, we surveyed 193 people living with overweight and obesity (“patients”), and 104 healthcare professionals (“HCPs”/doctors) who prescribe weight-loss medications. The online survey asked patients and HCPs to choose between medications with different benefits and risks, to uncover what features are most important to them (eg, would they prefer a medication that helps lose more weight, even if it means more side effects?). We found that both patients and HCPs would prefer to take/prescribe weight-loss medication than go medication-free. Patients preferred to take medications with low risk of gastrointestinal side effects (nausea, diarrhea/vomiting), that would help them lose the most amount of weight, and were not too expensive. HCPs preferred to prescribe medications that would help their patients lose the most amount of weight, that had the highest chance of success, had low risk of gastrointestinal side effects, and low-cost. HCPs also thought patients were more afraid of injectable medications than they actually were (most patients said they did not mind injections). If HCPs have a better understanding of what their patients want from weight-loss medication, they can have more meaningful conversations and offer medications which align with patients’ personal values and long-term health goals. With this approach, patients are more likely to stick with treatment, which means better long-term results.
- 1 February 2024
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 18, 435-454
Open AccessPatient and Healthcare Professional Preferences for Prescription Weight Loss Medications in Australia: Two Discrete Choice Experiments
Purpose: Overweight and obesity are common in Australia and among the leading risk factors for ill health. Maintained weight loss of > 5– 10% can prevent and reduce the risk of obesity-related comorbidities. Prescription weight loss medications plus lifestyle interventions can result in additional weight loss compared with lifestyle interventions alone, but these medications are under-prescribed in Australia. Our aim was to develop a greater understanding of the treatment preferences of people with overweight or obesity and the healthcare practitioners (HCPs) who treat them. Participants and Methods: An online survey of Australian adults with overweight or obesity and treating HCPs was conducted in 2020. A discrete choice experiment (DCE) approach was used to determine what is most important to people when evaluating oral and injectable prescription weight loss medications. Participants were asked to choose between three hypothetical treatment alternatives: “Oral pill”; “Subcutaneous injection pen (replaceable needle)”; “Disposable subcutaneous injection pen (hidden needle)”; and an opt-out option (“None of these”). Results: The online survey and DCE were completed by 193 patients and 104 HCPs. For both patients and HCPs, all treatment alternatives (oral, replaceable injection and disposable injection) were preferred over the opt-out. Gastrointestinal side effects, followed by success rate, percentage body weight lost, and cost were the most important attributes to patients. For HCPs, percentage body weight loss was the most important treatment attribute, followed by success rate, gastrointestinal side effects and cost. While most patients reported relatively low needle fear, physicians reported relatively high perceived patient needle fear. Conclusion: Clinician-patient discussions about treatments for weight loss should cover the option of prescription weight loss medications, including injectable medications, which patients may be less apprehensive about than physicians believe. Treatments with a high success rate and low or manageable risk of gastrointestinal side effects may be preferred over alternatives. Plain Language Summary: Overweight and obesity are the leading cause of health problems in Australia. Medications can be effective for people with this condition when combined with diet and exercise changes, but weight-loss medications in Australia are under-used. To understand why, we surveyed 193 people living with overweight and obesity (“patients”), and 104 healthcare professionals (“HCPs”/doctors) who prescribe weight-loss medications. The online survey asked patients and HCPs to choose between medications with different benefits and risks, to uncover what features are most important to them (eg, would they prefer a medication that helps lose more weight, even if it means more side effects?). We found that both patients and HCPs would prefer to take/prescribe weight-loss medication than go medication-free. Patients preferred to take medications with low risk of gastrointestinal side effects (nausea, diarrhea/vomiting), that would help them lose the most amount of weight, and were not too expensive. HCPs preferred to prescribe medications that would help their patients lose the most amount of weight, that had the highest chance of success, had low risk of gastrointestinal side effects, and low-cost. HCPs also thought patients were more afraid of injectable medications than they actually were (most patients said they did not mind injections). If HCPs have a better understanding of what their patients want from weight-loss medication, they can have more meaningful conversations and offer medications which align with patients’ personal values and long-term health goals. With this approach, patients are more likely to stick with treatment, which means better long-term results.
- Open Access
- 9 January 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (1)
Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor‐mutant non‐small cell lung cancer
Introduction: Evidence is limited on preferences of Japanese patients and physicians in treatment for epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC). Several oral or intravenous novel agents for EGFR exon 20 insertions are under development. The aim of our study was to investigate which attributes of novel treatments influenced selection of oral or intravenous agents among treated patients and treating physicians in Japan.Methods: The study was designed by board‐certified oncologists, patient representatives, and analytics specialists. Eligible participants completed an online survey with a discrete choice experiment presenting two treatment profiles described by attributes: mode of administration (oral or intravenous); frequency of administration; overall response rate (ORR); average progression‐free survival (PFS); chance of experiencing severe side effects (SEs); mild–moderate gastrointestinal SEs; mild–moderate skin‐related SEs; and patient out‐of‐pocket costs.Results: Fifty‐four patients (all self‐reported EGFR‐mutant) and 74 physicians participated from December 2021 to August 2022. All attributes being equal, there was greater preference for oral administration. However, there was greater preference for intravenous over oral, when ORR and PFS improved by 10% and 1 month, and severe SEs reduced by 10%. Physicians exhibited greater preference for PFS compared to patients (p < 0.01). Ranked order of attribute importance was as follows: (1) PFS; (2) ORR; (3) severe SEs, expressed by patients and physicians alike.Conclusions: Our study revealed Japanese physician and patient preferences in treatment options for EGFR‐mutant NSCLC. Compared to the strong preference for a more efficacious drug, the preference of oral versus intravenous revealed a smaller impact.
- 9 January 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (1)
Open AccessTreatment preferences among Japanese patients and physicians for epidermal growth factor receptor‐mutant non‐small cell lung cancer
Introduction: Evidence is limited on preferences of Japanese patients and physicians in treatment for epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC). Several oral or intravenous novel agents for EGFR exon 20 insertions are under development. The aim of our study was to investigate which attributes of novel treatments influenced selection of oral or intravenous agents among treated patients and treating physicians in Japan.Methods: The study was designed by board‐certified oncologists, patient representatives, and analytics specialists. Eligible participants completed an online survey with a discrete choice experiment presenting two treatment profiles described by attributes: mode of administration (oral or intravenous); frequency of administration; overall response rate (ORR); average progression‐free survival (PFS); chance of experiencing severe side effects (SEs); mild–moderate gastrointestinal SEs; mild–moderate skin‐related SEs; and patient out‐of‐pocket costs.Results: Fifty‐four patients (all self‐reported EGFR‐mutant) and 74 physicians participated from December 2021 to August 2022. All attributes being equal, there was greater preference for oral administration. However, there was greater preference for intravenous over oral, when ORR and PFS improved by 10% and 1 month, and severe SEs reduced by 10%. Physicians exhibited greater preference for PFS compared to patients (p < 0.01). Ranked order of attribute importance was as follows: (1) PFS; (2) ORR; (3) severe SEs, expressed by patients and physicians alike.Conclusions: Our study revealed Japanese physician and patient preferences in treatment options for EGFR‐mutant NSCLC. Compared to the strong preference for a more efficacious drug, the preference of oral versus intravenous revealed a smaller impact.